

# CITATION REPORT

List of articles citing

Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community

DOI: 10.1007/s40273-015-0335-2

Pharmacoeconomics, 2016, 34, 227-44.

**Source:** <https://exaly.com/paper-pdf/65764007/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
84	Consensus framework for HEEs of vaccines in Europe. <i>PharmacoEconomics &amp; Outcomes News</i> , <b>2015</b> , 740, 2-2	0.1	
83	Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China. <i>Pediatric Infectious Disease Journal</i> , <b>2016</b> , 35, e353-e361	3.4	20
82	Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges. <i>Pharmacoeconomics</i> , <b>2016</b> , 34, 723-31	4.4	7
81	Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. <i>Pharmacoeconomics</i> , <b>2016</b> , 34, 1299-1308	4.4	19
80	Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. <i>BMC Infectious Diseases</i> , <b>2016</b> , 16, 153	4	31
79	A systematic review of health economic evaluations of vaccines in Brazil. <i>Human Vaccines and Immunotherapeutics</i> , <b>2017</b> , 13, 1-12	4.4	6
78	Evaluating Frameworks That Provide Value Measures for Health Care Interventions. <i>Value in Health</i> , <b>2017</b> , 20, 185-192	3.3	36
77	Vaccines are different: A systematic review of budget impact analyses of vaccines. <i>Vaccine</i> , <b>2017</b> , 35, 2781-2793	4.1	5
76	Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review. <i>Vaccine</i> , <b>2017</b> , 35, 3153-3161	4.1	12
75	A systematic review of the health economic consequences of quadrivalent influenza vaccination. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2017</b> , 17, 249-265	2.2	31
74	Loss of chance associated with sub-optimal HPV vaccination coverage rate in France. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , <b>2017</b> , 3, 73-79	4.6	7
73	Improving accountability in vaccine decision-making. <i>Expert Review of Vaccines</i> , <b>2017</b> , 16, 1057-1066	5.2	7
72	Inclusion of the value of herd immunity in economic evaluations of vaccines. A systematic review of methods used. <i>Vaccine</i> , <b>2017</b> , 35, 6828-6841	4.1	16
71	Is the impact of childhood influenza vaccination less than expected: a transmission modelling study. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 258	4	14
70	3. How comprehensive can we be in the economic assessment of vaccines?. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1336044	3.7	5
69	[Seasonal flu vaccination for older people: Evaluation of the adjuvanted vaccine. Positioning report]. <i>Revista Espanola De Geriatria Y Gerontologia</i> , <b>2017</b> , 52 Suppl 2, 1-14	1.7	
68	Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0172414	3.7	5

67	Cost-effectiveness of human papillomavirus vaccination in Germany. <i>Cost Effectiveness and Resource Allocation</i> , <b>2017</b> , 15, 18	2.4	15
66	2. How is the economic assessment of vaccines performed today?. <i>Journal of Market Access &amp; Health Policy</i> , <b>2017</b> , 5, 1335163	3.7	7
65	Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. <i>Health Policy and Planning</i> , <b>2018</b> , 33, 204-214	3.4	8
64	Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study. <i>BMC Medicine</i> , <b>2018</b> , 16, 3	11.4	16
63	Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance. <i>Lancet Infectious Diseases</i> , <b>2018</b> , 18, e204-e213	25.5	34
62	[Seasonal flu vaccination for older people: Evaluation of the quadrivalent vaccine. Positioning report]. <i>Revista Espanola De Geriatria Y Gerontologia</i> , <b>2018</b> , 53 Suppl 2, 185-202	1.7	2
61	Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , <b>2018</b> , 21, 1133-1149	3.3	61
60	Evaluation of the Impact of a Rotavirus Vaccine Program on Pediatric Acute Gastroenteritis Hospitalizations: Estimating the Overall Effect Attributable to the Program as a Whole and as a Per-Unit Change in Rotavirus Vaccine Coverage. <i>American Journal of Epidemiology</i> , <b>2018</b> , 187, 2029-2037	3.8	3
59	Selection and Interpretation of Scientific Evidence in Preparation for Policy Decisions: A Case Study Regarding Introduction of Rotavirus Vaccine Into National Immunization Programs in Sweden, Norway, Finland, and Denmark. <i>Frontiers in Public Health</i> , <b>2018</b> , 6, 131	6	4
58	Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197905	3.7	7
57	Guidelines for multi-model comparisons of the impact of infectious disease interventions. <i>BMC Medicine</i> , <b>2019</b> , 17, 163	11.4	22
56	Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	11
55	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , <b>2019</b> , 8, 100184	4.6	17
54	Why should we apply ABM for decision analysis for infectious diseases?-An example for dengue interventions. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221564	3.7	9
53	Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain. <i>Human Vaccines and Immunotherapeutics</i> , <b>2019</b> , 15, 1949-1961	4.4	9
52	Seasonal influenza in Spain: Clinical and economic burden and vaccination programmes. <i>Medicina Clínica (English Edition)</i> , <b>2019</b> , 153, 16-27	0.3	0
51	[The development of vaccination policy]. <i>Revue Des Maladies Respiratoires</i> , <b>2019</b> , 36, 1038-1046	0	1
50	Mathematical modelling for antibiotic resistance control policy: do we know enough?. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 1011	4	21

49	Seasonal influenza in Spain: Clinical and economic burden and vaccination programmes. <i>Medicina Clínica</i> , <b>2019</b> , 153, 16-27	1	3
48	Impact of vaccines on antimicrobial resistance. <i>International Journal of Infectious Diseases</i> , <b>2020</b> , 90, 188-196	3.6	47
47	Commentary: Why Has Uptake of Pneumococcal Vaccines for Children Been So Slow? The Perils of Undervaluation. <i>Pediatric Infectious Disease Journal</i> , <b>2020</b> , 39, 145-156	3.4	8
46	Economic evaluation of meningococcal vaccines: considerations for the future. <i>European Journal of Health Economics</i> , <b>2020</b> , 21, 297-309	3.6	10
45	Public preference for COVID-19 vaccines in China: A discrete choice experiment. <i>Health Expectations</i> , <b>2020</b> , 23, 1543-1578	3.7	50
44	Health economic evaluation of gene replacement therapies: methodological issues and recommendations. <i>Journal of Market Access &amp; Health Policy</i> , <b>2020</b> , 8, 1822666	3.7	11
43	A comprehensive framework for considering additional unintended consequences in economic evaluation. <i>Cost Effectiveness and Resource Allocation</i> , <b>2020</b> , 18, 27	2.4	2
42	Strengthening National Immunization Technical Advisory Groups in resource-limited settings: current and potential linkages with polio national certification committees. <i>Health Research Policy and Systems</i> , <b>2020</b> , 18, 116	3.7	1
41	Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits. <i>Frontiers in Public Health</i> , <b>2020</b> , 8, 261	6	2
40	Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling Consortium. <i>PLoS Neglected Tropical Diseases</i> , <b>2020</b> , 14, e0008033	4.8	28
39	Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective. <i>Value in Health</i> , <b>2021</b> , 24, 105-111	3.3	4
38	Health Economics of Vaccines: From Current Practice to Future Perspectives. <i>Value in Health</i> , <b>2021</b> , 24, 1-2	3.3	4
37	Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?. <i>Value in Health</i> , <b>2021</b> , 24, 86-90	3.3	2
36	Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018. <i>Value in Health</i> , <b>2021</b> , 24, 61-66	3.3	1
35	Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. <i>Value in Health</i> , <b>2021</b> , 24, 91-104	3.3	5
34	Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2021</b> , 21, 235-245	2.2	1
33	Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 17, 1825-1833	4.4	0
32	Opposing vaccine hesitancy during the COVID-19 pandemic - A critical commentary and united statement of an international osteopathic research community. <i>International Journal of Osteopathic Medicine</i> , <b>2021</b> , 39, A1-A6	1.9	1

31	Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model. <i>PLoS ONE</i> , <b>2021</b> , 16, e0251644	3.7	1
30	Inclusion of Additional Unintended Consequences in Economic Evaluation: A Systematic Review of Immunization and Tuberculosis Cost-Effectiveness Analyses. <i>PharmacoEconomics - Open</i> , <b>2021</b> , 5, 587-603 <sup>2,1</sup>	3.7	1
29	The CAPACITI Decision-Support Tool for National Immunization Programs. <i>Value in Health</i> , <b>2021</b> , 24, 1150-1157	3.3	2
28	Realising the broader value of vaccines in the UK. <i>Vaccine: X</i> , <b>2021</b> , 8, 100096	3.8	1
27	Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. <i>Applied Health Economics and Health Policy</i> , <b>2021</b> , 1	3.4	1
26	How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations. <i>Value in Health</i> , <b>2021</b> , 24, 1391-1399	3.3	1
25	Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries. <i>Journal of Medical Economics</i> , <b>2021</b> , 24, 1098-1107	2.4	1
24	On time horizons in health economic evaluations. <i>Health Policy and Planning</i> , <b>2020</b> , 35, 1237-1243	3.4	14
23	From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233526	3.7	7
22	Impact and cost-effectiveness of nonavalent human papillomavirus vaccination in Switzerland: insights from a dynamic transmission model.		
21	Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.. <i>Applied Health Economics and Health Policy</i> , <b>2022</b> , 1	3.4	
20	Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease. <i>Infectious Diseases and Therapy</i> , <b>2021</b> ,	6.2	0
19	Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines.. <i>Applied Health Economics and Health Policy</i> , <b>2022</b> , 1	3.4	0
18	The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines.. <i>Expert Review of Vaccines</i> , <b>2022</b> , 1-13	5.2	0
17	Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.. <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 1-10	4.4	0
16	A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.. <i>European Journal of Health Economics</i> , <b>2022</b> , 1	3.6	0
15	Four Aspects Affecting Health Economic Decision Models and Their Validation.. <i>Pharmacoeconomics</i> , <b>2021</b> , 40, 241	4.4	0
14	Economic burden of varicella in Europe in the absence of universal varicella vaccination.. <i>BMC Public Health</i> , <b>2021</b> , 21, 2312	4.1	2

13	Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: a systematic literature review.. <i>Human Vaccines and Immunotherapeutics</i> , <b>2022</b> , 1-11	4.4	
12	Table_1.DOCX. <b>2020</b> ,		
11	Acceptance and application of a broad population health perspective when evaluating vaccine.. <i>Vaccine</i> , <b>2022</b> ,	4.1	o
10	Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom. <i>Journal of Health Economics and Outcomes Research</i> , <b>2022</b> , 9,	1.6	
9	Economic evaluations of interventions against viral pandemics: a scoping review. <i>Public Health</i> , <b>2022</b> , 208, 72-79	4	
8	Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom. <i>Journal of Health Economics and Outcomes Research</i> , <b>2022</b> , 9, 140-150	1.6	
7	COVID-19 Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A CostBenefit Analysis. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19, 7848	4.6	1
6	Using Health Economics to Inform Immunization Policy Across All Levels of Government. <i>PharmacoEconomics - Open</i> ,	2.1	
5	Cost-effectiveness analysis of a maternal pneumococcal vaccine in low-income, high-burden settings such as Sierra Leone.		
4	A guideline for economic evaluations of vaccines and immunization programs in China.		o
3	Placing a value on increased flexible vaccine manufacturing capacity for future pandemics. <b>2023</b> , 41, 2317-2319		o
2	Coste-efectividad de la vacunaci3n universal infantil frente a la hepatitis A en Espa3a: un enfoque dinámico. <b>2023</b> , 37, 102292		o
1	The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework. <b>2023</b> , 21, 373-384		o